Antidepressant-like profile and MAO-A inhibitory activity of 4-propyl-2H-benzo[h]-chromen-2-one

• Published in: Life sciences (1973) 2010-05, Vol.86 (21), p.819-824
• Main Authors: Vergel, Nadezdha E., López, José L., Orallo, Francisco, Viña, Dolores, Buitrago, Diana M., del Olmo, Esther, Mico, Juan A., Guerrero, Mario F.
• Format: Article
• Language: English
• Subjects: Animals; Antidepressant; Antidepressive Agents - pharmacology; Behavior, Animal - drug effects; Central Nervous System - drug effects; Chromones - pharmacology; Coumarin; Dose-Response Relationship, Drug; Drug design; Male; MAO-A; Mice; Mice, Inbred ICR; Monoamine oxidase; Monoamine Oxidase Inhibitors - pharmacology; Seizures - drug therapy; Sleep - drug effects
• ISSN: 0024-3205; 1879-0631
• DOI: 10.1016/j.lfs.2010.04.001

To evaluate the central nervous pharmacological profile of 4-propyl-2H-benzo[h]-chromen-2-one (FCS-304) in ICR mice and its monoamine oxidase inhibitor activity. FCS-304 was evaluated in screening test of central nervous system in ICR mice and against MAO activity. FCS-304 (25–200 mg/Kg, p.o.) significantly reduced immobility time during the forced swimming test (FST) and tail suspension test (TST), but did not show effects in the rota-rod tests, maximal electroshock seizures (MES), pentylenetetrazole seizures, light–dark box, barbiturate sleeping time and cold plate tests. Furthermore, FCS-304 inhibited monoamine oxidase A (MAO-A) with IC 50: 2.28 ± 0.15 µM, but not MAO-B. These results suggest that FCS-304 could elicit antidepressant effects related to MAO-A inhibitory activity.